Ipamorelin (2mg x 10), CJC-1295 no DAC (2mg x 10)

Ipamorelin and CJC-1295 no DAC (Mod GRF 1-29) are synthetic research peptides used together in experimental models to investigate growth hormone axis regulation and somatotropic signaling mechanisms. Ipamorelin is a selective pentapeptide growth hormone secretagogue that acts as an agonist of the growth hormone secretagogue receptor (GHS-R1a), activating Gq/PLC and calcium-dependent intracellular signaling involved in GH release while demonstrating minimal interaction with other pituitary hormones in preclinical systems. CJC-1295 no DAC is a stabilized analog of growth hormone–releasing hormone (GHRH 1-29) that selectively activates the GHRH receptor, stimulating adenylate cyclase and cAMP-mediated signaling in pituitary somatotrophs. Preclinical research employs the combined activation of GHS-R1a and GHRH receptors to examine synergistic GH secretion, hypothalamic–pituitary feedback mechanisms, and endocrine receptor pharmacology in controlled laboratory settings.